Monthly doses of
palivizumab, an RSV-specific
monoclonal antibody, reduce RSV-related hospitalizations (RSVH) in high-risk children; however, no specific
palivizumab level has been correlated with disease severity in humans. A post hoc analysis of a previous randomized, placebo-controlled trial evaluated the relationship between serum
palivizumab level at the time of RSVH and disease severity. Pediatric intensive care unit (PICU) admission was the primary severity marker. Relationships were evaluated between disease severity and gestational age, age at enrollment, age at RSVH, presence of
bronchopulmonary dysplasia, sex, race, multiple birth, household smoking, daycare attendance, sibling(s), family history of atopy, duration between most recent
palivizumab dose and RSVH, and
palivizumab level at RSVH. Forty-two (87.5%) of 48
palivizumab recipients with RSVH had
palivizumab levels drawn; 11 were admitted to the PICU. Mean
palivizumab levels were lower in PICU-admitted subjects (47.2 μg/mL) vs. non-PICU subjects (98.7 μg/mL; P < 0.0001); there were no statistically significant differences in other variables examined. The probability of PICU admission declined with higher
palivizumab levels; there were no PICU admissions with levels ≥ 92 μg/mL. In multivariate analyses,
palivizumab level was the only independent predictor of PICU admission (P = 0.009).
Palivizumab level also correlated with duration of RSVH and PICU stay, supplemental
oxygen use and duration, and
mechanical ventilation use and duration (P < 0.05). Higher
palivizumab level was associated with decreased disease severity in high-risk infants with RSVH. Findings suggest that
palivizumab level has clinical relevance, and adherence to timely monthly dosing may confer additional protection among high-risk children receiving
palivizumab.